Latham & Watkins Advised on Janux Therapeutics’ Pricing of US $60 Million Underwritten Offering

Latham & Watkins Advised on Janux Therapeutics’ Pricing of US $60 Million Underwritten Offering

Latham & Watkins has advised on Janux Therapeutics’ pricing of US $60 million underwritten offering of common stock and pre-funded warrants.

Janux Therapeutics, Inc., clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, had announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares of common stock.

The gross proceeds from the offering to Janux are expected to be approximately US $60 million, before deducting underwriting discounts and commissions and offering expenses.

The Capital Markets practice team which acted and advised for the underwriter in the offering was led by San Diego Matt Bush, Partner; Richard Kim, Partner; with San Diego Associates Peter Simon and Rachel Staub.

The offering is expected to close on 19th July, 2023, subject to the satisfaction of customary closing conditions.